CREST-UK: Real-world effectiveness, safety and outpatient delivery of CPX-351 for first-line treatment of newly diagnosed therapy-related AML and AML with myelodysplasia-related changes in the UK.
Mehta P, Campbell V, Maddox J, Floisand Y, Kalakonda AJM, O'Nions J, Coats T, Nagumantry S, Hodgson K, Whitmill R, Amott I, Flynn G, Taussig D, Zhao R, Cunningham N, Roset M, Cuadras D, Medalla G, Kuter H, Park S, Legg A, Khan AB.
Mehta P, et al. Among authors: flynn g.
Br J Haematol. 2024 Oct;205(4):1326-1336. doi: 10.1111/bjh.19622. Epub 2024 Jul 8.
Br J Haematol. 2024.
PMID: 38977430
Clinical Trial.